Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. (MACULA)

Pfizer

Status: Completed

Conditions: Neovascular Age-related Macular Degeneration

Treatments: Drug: pegaptanib sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT00858208

A5751028

Details and patient eligibility

About

Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.

Full description

Eligible patients in routine clinical practice

Enrollment: 86 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

adults with neovascular age-related macula degeneration

Exclusion criteria

according to SmPC

Trial design

86 participants in 1 patient group

Patients with neovascular Age-Related Macula Degeneration

Treatment:

Drug: pegaptanib sodium